DDInter1294 DDInter262
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133]
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Enzalutamide {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Nilutamide {u} (Compound) resembles {v} (Compound) Nitisinone
Nitisinone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Modafinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Enzalutamide {u} may lead to a major life threatening interaction when taken with {v} Naloxegol
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cabozantinib
Nilutamide {u} (Compound) treats {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is treated by {v} (Compound) Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Nilutamide {u} (Compound) resembles {v} (Compound) Nitisinone
Nitisinone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cabozantinib
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cabozantinib
Nilutamide {u} (Compound) binds {v} (Gene) POR
POR {u} (Gene) is bound by {v} (Compound) Daunorubicin
Daunorubicin {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Nilutamide {u} (Compound) treats {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is palliated by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Nilutamide {u} (Compound) resembles {v} (Compound) Nitisinone
Nitisinone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Nilutamide {u} (Compound) binds {v} (Gene) POR
POR {u} (Gene) is upregulated by {v} (Compound) Thioridazine
Thioridazine {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Nilutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide may lead to a major life threatening interaction when taken with Cabozantinib
Nilutamide (Compound) resembles Nitisinone (Compound) and Nitisinone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Nilutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Nilutamide (Compound) treats prostate cancer (Disease) and prostate cancer (Disease) is treated by Etoposide (Compound) and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Nilutamide (Compound) resembles Nitisinone (Compound) and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Nilutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Nilutamide (Compound) binds POR (Gene) and POR (Gene) is bound by Daunorubicin (Compound) and Daunorubicin may lead to a major life threatening interaction when taken with Cabozantinib
Nilutamide (Compound) treats prostate cancer (Disease) and prostate cancer (Disease) is palliated by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Nilutamide (Compound) resembles Nitisinone (Compound) and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Nilutamide (Compound) binds POR (Gene) and POR (Gene) is upregulated by Thioridazine (Compound) and Thioridazine may lead to a major life threatening interaction when taken with Cabozantinib